DUBAI: Gulf Pharmaceutical Industries Julphar has announced its Strategy 2030, an effort to drive transformation that will contribute to higher shareholder returns. According to the Emirates News Agency, WAM, the company is on track to deliver revenue growth from its legacy products, and plans to launch over 100 new products between 2022 and 2030. It will leverage its in-house research and development capabilities and sign licensing agreements with top-tier pharma partners, as well as acquiring new products, WAM said. Dr. Essam Mohamed, CEO of Julphar, said: “Despite the enormous challenges and the global pandemic, we achieved one of the most successful strategic turnaround stories.” The company also plans to continue exploring new partnerships and launching new products in core therapeutic areas, investing in capital expenditures to improve operational efficiency, and expanding geographically to support its long-term growth plans.